TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2248109

Group type: EXPERIMENTAL
Intervention: Systematic exposure to drug-related cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment for drug dependence
Number of subjects: 0
Study: 7352840

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Pheneizine sulfate
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 6305670

Group type: EXPERIMENTAL
Intervention: ranitidine (150 mg bid)
Number of subjects: 6
Study: 31389755

Group type: EXPERIMENTAL
Intervention: Immediate loading of implants (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed loading of implants (n = 10)
Number of subjects: 20
Study: 29401297

Group type: EXPERIMENTAL
Intervention: Top-down treatment
Number of subjects: 119

Group type: COMPARATOR
Intervention: Step-up treatment
Number of subjects: 119
Study: 27762512

Group type: EXPERIMENTAL
Intervention: Noradrenaline (0.5-3 mg/h)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Terlipressin (0.5-2 mg/6h)
Number of subjects: 41
Study: 24907142

Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine/rilpivirine
Number of subjects: 32
Study: 22314064

Group type: EXPERIMENTAL
Intervention: Study scrubs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control scrubs
Number of subjects: 30
Study: 21294404

Group type: EXPERIMENTAL
Intervention: 10 mg simvastatin in the morning
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo in the evening
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Evening simvastatin administration
Number of subjects: 52
Study: 17506592

Group type: EXPERIMENTAL
Intervention: Clodronic acid 800 mg plus elemental calcium 500 mg and 400 IU of vitamin D daily
Number of subjects: 79

Group type: COMPARATOR
Intervention: Calcium and vitamin D only (Control)
Number of subjects: 79
Study: 15767608

Group type: EXPERIMENTAL
Intervention: Home-based balance-training program using a wobble board for 6 weeks (daily) and 6 months (weekly)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Home-based balance-training program using a wobble board
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (testing only)
Number of subjects: 127
Study: 12093429

Group type: EXPERIMENTAL
Intervention: Plant stanol ester (PSE) spread, 2 g daily for 4 weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: Plant stanol ester (PSE) spread, 3 g daily
Number of subjects: 105
Study: 10601920

Group type: EXPERIMENTAL
Intervention: 60 microg/d estradiol vaginal ring
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 140 microg/d estradiol vaginal ring
Number of subjects: 35
Study: 7477146

Group type: EXPERIMENTAL
Intervention: Exercise plus antihypertensive medication
Number of subjects: 46

Group type: COMPARATOR
Intervention: Antihypertensive medication alone
Number of subjects: 46
Study: 2011406

Group type: EXPERIMENTAL
Intervention: Molsidomine (4 mg once acutely, 3 times 4 mg a day for 3 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Molsidomine (after 3 weeks treatment)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7009019

Group type: EXPERIMENTAL
Intervention: Pyridoxine hydrochloride (20 mgs twice daily)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 31899491

Group type: EXPERIMENTAL
Intervention: Senior Dance (Dance plus education)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Education alone (control group)
Number of subjects: 82
Study: 30389226

Group type: EXPERIMENTAL
Intervention: Low-dose VWG OIT (1445 mg of wheat protein)
Number of subjects: 46

Group type: COMPARATOR
Intervention: High-dose VWG OIT (maximum, 2748 mg of wheat protein)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-dose VWG OIT
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 28826170

Group type: EXPERIMENTAL
Intervention: Manipulation Techniques (MT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Home Exercise (HE)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both MT and HE
Number of subjects: 27
Study: 27314172

Group type: EXPERIMENTAL
Intervention: MeDiet + extra‐virgin olive oil (EVOO)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: MeDiet + nuts (walnuts, almonds, and hazelnuts)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control low‐fat diet
Number of subjects: 351
Study: 25039364

Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction therapy with reduced doses of tacrolimus, steroids, and mycophenolate mofetil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thymoglobulin in association with standard dose immunosuppression (IS)
Number of subjects: 60
Study: 21824444

Group type: EXPERIMENTAL
Intervention: 500 mg HCA with a high-carbohydrate meal (2 g carbohydrate/kg body weight, 80 % carbohydrate, 8 % fat, 12 % protein)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 mg HCA with a high-carbohydrate meal
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 mg HCA
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 20818193

Group type: EXPERIMENTAL
Intervention: Nordic walking (NW)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Exercise on Prescription (EP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 68
Study: 16973659

Group type: EXPERIMENTAL
Intervention: 4 mg intravitreal triamcinolone (ivTA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 6 mg intravitreal triamcinolone (ivTA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 8 mg intravitreal triamcinolone (ivTA)
Number of subjects: 63
Study: 15718403

Group type: EXPERIMENTAL
Intervention: Microgravity (0 G)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypergravity (1.8 G)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal gravity (1 G)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypergravity (1.7 G)
Number of subjects: 12
Study: 12111110

Group type: EXPERIMENTAL
Intervention: Fludarabine treatment (25 mg/m² daily for 5 days every 28 days)
Number of subjects: 192
Study: 10502181

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced EUS with air-filled albumin (0.22 mL/kg) intravenously injected at a rate of 1 mL/sec for 10 minutes
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced EUS
Number of subjects: 42
Study: 7560251

Group type: EXPERIMENTAL
Intervention: Dolasetron (0.6 to 5.0 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dolasetron (doses > or = 3.0 mg/kg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dolasetron
Number of subjects: 80
Study: 2080113

Group type: EXPERIMENTAL
Intervention: Rehab group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 436308

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cimetidine (Control)
Number of subjects: 15
Study: 31274484

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (15 mg/kg) started 20 min before induction, during surgery, and for the first postoperative 24 hours.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Normal saline (control group).
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (15 mg/kg).
Number of subjects: 250
Study: 28599889

Group type: EXPERIMENTAL
Intervention: Thiopentone (7.5 mg kg−1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propofol (3 mg kg−1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alfaxalone (1.5 mg kg−1)
Number of subjects: 6
Study: 26595300

Group type: EXPERIMENTAL
Intervention: Expressive Writing
Number of subjects: 113

Group type: COMPARATOR
Intervention: Neutral Writing
Number of subjects: 113
Study: 23249429

Group type: EXPERIMENTAL
Intervention: Preload group (vegetable salad, yogurt, and water consumed 15 min before the main meal)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (vegetable salad, yogurt, and water consumed with meal)
Number of subjects: 60
Study: 21261516

Group type: EXPERIMENTAL
Intervention: Herbal tea containing fenugreek (Group 1, n=22)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (Group 2, n=22)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (Group 3, n=22)
Number of subjects: 66
Study: 18188496

Group type: EXPERIMENTAL
Intervention: Short latency afferent inhibition (SAI) test in SIVD patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Short latency afferent inhibition (SAI) test in control subjects
Number of subjects: 20
Study: 16006055

Group type: EXPERIMENTAL
Intervention: Referral to an alcohol health worker (AHW) who delivered a brief intervention (n = 287)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Information only control (n = 312)
Number of subjects: 599
Study: 12900677

Group type: EXPERIMENTAL
Intervention: Resistance training (80% of single-repetition maximal lift)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (light yoga and breathing exercises)
Number of subjects: 42
Study: 10884257

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/kg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Intravenous diazepam (0.3 mg/kg)
Number of subjects: 47
Study: 8633935

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) treatment
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 142
Study: 1533530

Group type: EXPERIMENTAL
Intervention: terfenadine 120 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: loratadine 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 3880657

Group type: EXPERIMENTAL
Intervention: Vincristine (0.4 mg/m2/1/day by continuous infusion)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Vinblastine (1.7 mg/m2/1/day by continuous infusion)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Vindesine (1.2 mg/m2/1/day by continuous infusion)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Vindesine (1.2 mg/m2/1/day intermittent bolus)
Number of subjects: 99
Study: 31877141

Group type: EXPERIMENTAL
Intervention: Azithromycin (500mg once-daily for 14 days)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Ciprofloxacin (500mg twice-daily for 14 days)
Number of subjects: 81
Study: 29511334

Group type: EXPERIMENTAL
Intervention: D-amphetamine (20 mg oral)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Methamphetamine (20 mg oral)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 27460616

Group type: EXPERIMENTAL
Intervention: Childhood sexual abuse
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Childhood emotional abuse
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Childhood physical abuse
Number of subjects: 228
Study: 25944519

Group type: EXPERIMENTAL
Intervention: Combination 17β-estradiol/progesterone capsule
Number of subjects: 66

Group type: COMPARATOR
Intervention: Coadministered reference products of estradiol and progesterone
Number of subjects: 66
Study: 23455721

Group type: EXPERIMENTAL
Intervention: 0.7‐Hz rTMS stimulation at 100 % of the motor cortex excitability threshold on the prefrontal cortex of one randomly assigned hemisphere
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rTMS on the left hemisphere
Number of subjects: 12

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rTMS on the right hemisphere
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 12
Study: 21282560

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 80 mg
Number of subjects: 1291

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 40 mg
Number of subjects: 1291

Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 1291

Group type: COMPARATOR
Intervention: Olmesartan 40 mg
Number of subjects: 1291
Study: 20306755

Group type: EXPERIMENTAL
Intervention: Low pressure pneumoperitoneum (7-10 mm Hg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard pressure pneumoperitoneum (12-14 mm Hg)
Number of subjects: 60
Study: 16492849

Group type: EXPERIMENTAL
Intervention: Programmed Intermittent Epidural Bolus (PIEB) - 6 mL bolus every 30 min starting 45 min after intrathecal injection
Number of subjects: 126

Group type: COMPARATOR
Intervention: Continuous Epidural Infusion (CEI) - 12 mL/h infusion starting 15 min after intrathecal injection
Number of subjects: 126
Study: 14526630

Group type: EXPERIMENTAL
Intervention: Surgical intervention for malignant neoplasms
Number of subjects: 0
Study: 11096040

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) recommendation for men with ESRD
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) recommendation for patients with good compliance
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) recommendation for patients weighing less than 200 lb
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) recommendation for patients with residual renal function
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) recommendation for patients without diabetes
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) recommendation for patients living with family
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) recommendation based on nephrologists' years of practice
Number of subjects: 271
Study: 9346148

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Patient-controlled analgesia pump
Number of subjects: 68
Study: 7818648

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 1.25 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5.0 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bendrofluazide 1.25 mg and 5.0 mg
Number of subjects: 16
Study: 2453895

Group type: EXPERIMENTAL
Intervention: Hydromorphone (6 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (0.2 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.2 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.2 mg plus Naloxone 0.2 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg plus Naloxone 0.2 mg
Number of subjects: 6
Study: 27011262

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 0.25 mg/0.01 ml
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 0.625 mg/0.025 ml
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 8
Study: 27978532

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200mg plus paracetamol 325mg TID
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ibuprofen 400mg TID
Number of subjects: 80
Study: 25969894

Group type: EXPERIMENTAL
Intervention: MenABCWY formulations containing OMV components
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: 2 doses of OMV‐containing MenABCWY formulations
Number of subjects: 495

Group type: COMPARATOR
Intervention: MenABCWY or rMenB groups
Number of subjects: 495

Group type: COMPARATOR
Intervention: MenACWY‐CRM group
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 495
Study: 24391139

Group type: EXPERIMENTAL
Intervention: F4/AS01(B) booster administered alone
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: F4/AS01(B) booster administered after chloroquine (300 mg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Chloroquine (300 mg) administered 2 days before the booster
Number of subjects: 2
Study: 22244384

Group type: EXPERIMENTAL
Intervention: Bio‐Oss Collagen with implant placement (Group 1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bio‐Oss Collagen without implant placement (Group 2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (Group 3) - untreated sockets
Number of subjects: 25
Study: 20385995

Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: LV5FU2
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 349
Study: 18344895

Group type: EXPERIMENTAL
Intervention: H. pylori positive
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: H. pylori eradicated
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Presence of antral intestinal metaplasia (IM)
Number of subjects: 1790

Group type: COMPARATOR
Intervention: H. pylori eradication
Number of subjects: 1790
Study: 15996025

Group type: EXPERIMENTAL
Intervention: Ninjinyoeito (NYT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (without NYT)
Number of subjects: 23
Study: 12188104

Group type: EXPERIMENTAL
Intervention: Rivastigmine (6-12 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10480420

Group type: EXPERIMENTAL
Intervention: MMF-based triple therapy (1.0 g of MMF twice daily from postoperative day 2, n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (CsA-Neoral and steroids, n=50)
Number of subjects: 100
Study: 9168850

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 50, 100, or 250 micrograms
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 or 250 micrograms
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study: 7681647

Group type: EXPERIMENTAL
Intervention: Rapid antigen detecting test and a 10-day oral penicillin course
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid antigen detecting test and intramuscular benzathin penicillin G
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular benzathin penicillin G for all children with pharyngitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of group A streptococcal pharyngitis
Number of subjects: 0
Study: 2877645

Group type: EXPERIMENTAL
Intervention: Infrasonde
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cuff measurements by trained physician assistant (PA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cuff measurements by clinic nurses (casual readings)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cuff measurements by clinic nurses (serial readings)
Number of subjects: 36
Study: 31747468

Group type: EXPERIMENTAL
Intervention: Endurance training + GTE (ET + GTE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endurance training + placebo (ET + P)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no exercise) + placebo
Number of subjects: 30
Study: 30031553

Group type: EXPERIMENTAL
Intervention: Mechanical Diagnosis and Therapy (MDT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MDT + LUMOback
Number of subjects: 22

Group type: COMPARATOR
Intervention: MDT
Number of subjects: 22
Study: 26288118

Group type: EXPERIMENTAL
Intervention: mirabegron 50 mg/day
Number of subjects: 1987

Group type: COMPARATOR
Intervention: tolterodine ER 4 mg/day
Number of subjects: 1987

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1987
Study: 24899242

Group type: EXPERIMENTAL
Intervention: Mindfulness training program (weekly group-based classes in mindfulness practice, 2 ½ hours, for 8 weeks plus a 7-hour Saturday session in Week 6)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care (routine total joint arthroplasty)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mindfulness training program
Number of subjects: 150
Study: 22235059

Group type: EXPERIMENTAL
Intervention: Action observation (EG) - watching video footage of daily routine tasks and imitating movements for 2 minutes with therapist assistance.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (CG) - static images without animals or human beings and simulated shoulder and elbow joint mobilization activities.
Number of subjects: 102
Study: 20397265

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) + Pringle maneuver (PM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Pringle maneuver (PM) alone
Number of subjects: 61
Study: 19558064

Group type: EXPERIMENTAL
Intervention: Early enteric feeding via a nasoduodenal tube
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasoduodenal tube feeding
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasoduodenal tube placement and confirmation by serial pH monitoring and radiological examination
Number of subjects: 40
Study: 15782753

Group type: EXPERIMENTAL
Intervention: Counseling about cessation within the past year
Number of subjects: 1941

Group type: EXPERIMENTAL
Intervention: Referral to a cessation program
Number of subjects: 1941

Group type: EXPERIMENTAL
Intervention: Prescription for nicotine patches
Number of subjects: 1941

Group type: EXPERIMENTAL
Intervention: Intention to quit smoking
Number of subjects: 1941

Group type: EXPERIMENTAL
Intervention: Quit attempts in the prior year
Number of subjects: 1941
Study: 12056714

Group type: EXPERIMENTAL
Intervention: Audiotaping of follow-up consultations
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no audiotaping)
Number of subjects: 52
Study: 10616628

Group type: COMPARATOR
Intervention: Family support alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic psychosocial interventions based on an assessment of need
Number of subjects: 0
Study: 7577208

Group type: COMPARATOR
Intervention: Cisplatin plus etoposide (standard chemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin plus paclitaxel
Number of subjects: 0
Study: 7680493

Group type: EXPERIMENTAL
Intervention: Bovine myelin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control protein
Number of subjects: 30
Study: 3083100

Group type: EXPERIMENTAL
Intervention: Unloaded pedalling (0 W), 50 W, 100 W, 150 W
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyperventilation at rate 24/min and normal tidal volume
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyperventilation at normal rate and tidal volume of 1.5 l
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyperventilation at rate 24/min and tidal volume of 1.5 l
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyperventilation at rate 24/min and tidal volume of 1.4 l
Number of subjects: 9
Study: 30251010

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (120 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60